Ob/Gyn Medical News about Hormone Replacement Therapy Postmenopause

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Issues in postmenopausal hormone therapy: depression, endometrial health, and discontinuation
Sexuality, Reproduction & Menopause, 10/09/09

Patients and physicians are confused by conflicting reports of the efficacy and safety of hormone therapy, both FDA–approved and non–FDA–approved bioidentical, as evidenced by the decline in women using hormone therapy despite their desire to continue therapy. A large percentage of postmenopausal women report being worried by news reports that the 2002 WHI report showed that hormone therapy is dangerous. Physicians report that the ambiguous and inconclusive results of the WHI reports sent mixed messages to physicians and patients that compromised physicians’ ability to discuss hormone therapy with their postmenopausal patients. Regardless of the type of preparation used, use of hormone therapy must consider the varying formulations available, pharmacodynamics, and individual patient factors.

<< Previous
Emergency contraception: An update for providers

Next >>
Adjuvant radiotherapy and chemoradiation after surgery for...